The CD30 antibody-drug conjugate brentuximab vedotin is newly approved for use in classical Hodgkin lymphoma as well as mycosis fungoides, leaving the predictable gap in data on whether it is safe to administer radiation in close proximity. A retrospective review of outcomes with radiation delivered within three weeks of brentuximab vedotin (n=44) suggests the addition of radiation, particularly at higher doses, may contribute to grade 2+ heme toxicity, as experienced by roughly 1 in 5 patients. Otherwise, all remaining grade 2+ toxicities were rare. | Wu, Adv Radiat Oncol 2023
